Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for No-reflow in STEMI
NCT02507128Unknown
- Start
- Jul 2015
- Primary completion
- Jul 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of liraglutide in ST-segment elevation myocardial infarction (STEMI) (2 arms). Primary endpoint: Change in the prevalence of no-reflow. Status: unknown.
02
Drugs
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT02507128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02507128.